PHARMExcel are delighted to announce their future collaboration with DIOSynVax to support the delivery of their forthcoming clinical trial program.
This programme, (supported by CEPI funding), will provide the infrastructure to help design and select the lead antigen through proof-of-concept preclinical studies, progressing to initial clinical development through Phase I/II studies. DIOSynVax aim to establish clinical proof of concept for a novel vaccine candidate with the potential to provide broad protection against Sarbecovirus, Merbecovirus, Embecovirus and Nobecovirus.